Isembyld approval leads the Sep. 5–11 FDA drug and device ledger (2026)

The FDA approval window from September 5 through September 11, 2026 produced one landmark novel therapeutic approval: Scholar Rock's Isembyld (apitegromab-mstn) for spinal muscular atrophy. The agency also posted new full generic approvals, efficacy and labeling supplements, and four early-window medical device clearances in its downloadable records. 1 2

The device portion represents an official captured ledger of available records for the seven-day period. The FDA monthly downloadable 510(k) file contains four clearance records dated September 5 and September 6, while the public database displays no records dated September 7 through September 11. The agency's premarket approval decision feed shows no new item-level PMA decisions during this weekly window. 3 4

At a glance

Action	FDA date	Approved indication or intended use	Sponsor / Applicant	Commercial and clinical read
Isembyld (apitegromab-mstn)	Sep. 11	Spinal muscular atrophy in patients age 2 and older receiving an SMN2-targeted therapy	Scholar Rock	First muscle-directed therapy approved for SMA; pairs with genetic therapies to address motor function.
Brivaracetam tablets	Sep. 8	Oral generic antiepileptic (ANDA 220136)	Zhejiang Jutai Pharm	Additional supply source for partial-onset seizure regimens.
Ibrutinib capsules	Sep. 8	Oral generic kinase inhibitor (ANDA 211182)	Hetero Labs Ltd V	Broadens generic competition for B-cell malignancy indications.
Tivozanib capsules	Sep. 8	Generic VEGFR TKI (ANDA 220307)	Glenmark Pharmaceuticals Limited	Tentative approval establishes manufacturing readiness ahead of patent expiry.
Isotretinoin capsules	Sep. 10	Oral generic retinoid (ANDA 220336)	Aurobindo Pharma Ltd	Expands generic alternatives in the iPLEDGE REMS distribution channel.
Spironolactone / Hydrochlorothiazide	Sep. 10	Oral diuretic combination (ANDA 220884)	Rubicon Research	Routine multi-source oral generic addition.
Ameluz gel (SUPPL-40)	Sep. 9	Topical efficacy supplement (NDA 208081)	Biofrontera	Regulatory efficacy action for aminolevulinic acid photodynamic therapy.
Hyrnuo tablets (SUPPL-1)	Sep. 9	Oral efficacy supplement (NDA 219972)	Bayer Healthcare	First efficacy supplement for sevabertinib.
Medical device clearances	Sep. 5–6	Four 510(k) clearances (K254135, K261684, K260396, K261131)	Multiple applicants	Early-week throughput across lipoplasty, vapocoolant, rTMS, and muscle stimulation.

Drug and biologic approvals

Isembyld: first muscle-targeted therapy for spinal muscular atrophy

The FDA approved Isembyld (apitegromab-mstn) on September 11, 2026, marking the thirty-ninth novel drug approval of the year. The approved indication covers the treatment of spinal muscular atrophy (SMA) in adult and pediatric patients 2 years of age and older who are currently receiving a survival motor neuron 2 (SMN2)-targeted therapy. 1 5

Apitegromab is a fully human monoclonal antibody designed to inhibit myostatin activation by binding selectively to pro-myostatin and latent myostatin forms in skeletal muscle. Existing standard-of-care treatments, including nusinersen (Spinraza), risdiplam (Evrysdi), and onasemnogene abeparvovec (Zolgensma), act on SMN protein production. Isembyld introduces a dual-mechanism regimen by targeting muscle mass and motor function directly on top of upstream SMN stabilization. 5

The therapeutic dose is 10 mg/kg administered once every four weeks by intravenous infusion. Administration requires a healthcare professional in an infusion center, hospital outpatient unit, or home infusion setting. Patient advocacy organization Cure SMA confirmed that Scholar Rock is coordinating with commercial insurers and government programs to establish coverage pathways for patients who meet the label criteria. 5

Commercial read

Isembyld transforms Scholar Rock from a clinical-stage development company into a commercial-stage rare disease enterprise. Sponsoring company disclosures estimate the global market opportunity for apitegromab in SMA at more than $2 billion. Financial analysts have modeled substantial commercial adoption; Jefferies analyst Amy Li initiated coverage on August 21 with a Buy rating and a $50 price target, projecting risk-adjusted peak global sales of $1.8 billion across SMA types 1 through 3. 6

The approval also provides non-dilutive liquidity. Scholar Rock's debt agreement with Blue Owl Capital makes up to $150 million in capital available upon FDA approval of apitegromab, extending the company's financial runway to support commercial deployment and manufacturing scale-up. The company ended 2025 with $367.6 million in cash, cash equivalents, and marketable securities. 7

Market trading in Scholar Rock shares (NASDAQ: SRRK) reflected steady valuation on approval day. Shares closed at $55.41 on September 11 on volume of 921,666 shares, compared to the prior close of $55.67. Clean equity research wires recorded no formal rating change or price target revision on approval day. Commercial traction will depend on payer formulary placement and physician willingness to layer monthly intravenous infusions onto existing oral or intrathecal treatment schedules.

Other captured Drugs@FDA actions

The Drugs@FDA recent approvals report captures final and tentative approvals, along with supplemental submissions approved between September 8 and September 10, 2026. 2

Generic approvals and supply additions

Application	Drug name	Dosage form	Applicant	Action type	Commercial context
ANDA 220136	Brivaracetam	Oral tablet	Zhejiang Jutai Pharm	Final approval	Adds generic manufacturing capacity against reference product Briviact.
ANDA 211182	Ibrutinib	Oral capsule	Hetero Labs Ltd V	Final approval	Expands generic supply for BTK inhibitor regimens in mantle cell lymphoma and CLL.
ANDA 220307	Tivozanib	Oral capsule	Glenmark Pharmaceuticals Limited	Tentative approval	Confirms technical bioequivalence; final market entry remains subject to patent and exclusivity expiry.
ANDA 220336	Isotretinoin	Oral capsule	Aurobindo Pharma Ltd	Final approval	Multi-source oral acne formulation operating under mandatory iPLEDGE risk management.
ANDA 220884	Spironolactone and Hydrochlorothiazide	Oral tablet	Rubicon Research	Final approval	Incremental commodity generic supply for hypertension management.

Commercial read: The full approvals for ibrutinib and brivaracetam provide multi-source price competition in high-expenditure oncology and neurology categories. Because tentative approvals grant commercial rights only upon patent or exclusivity expiration, Glenmark's tivozanib clearance represents an operational manufacturing milestone.

Efficacy and labeling supplements

Application	Product name	Active ingredient	Sponsor	Submission	Scope
NDA 208081	Ameluz	Aminolevulinic acid hydrochloride	Biofrontera	SUPPL-40	Approved efficacy supplement
NDA 219972	Hyrnuo	Sevabertinib	Bayer Healthcare	SUPPL-1	Approved efficacy supplement
NDA 209627	Annovera	Ethinyl estradiol; segesterone acetate	Mayne Pharma	SUPPL-8	Approved labeling supplement
ANDA 090429	Ropinirole hydrochloride	Ropinirole hydrochloride	Alembic Ltd	SUPPL-16, SUPPL-19	Approved labeling supplements
ANDA 040671	Triamcinolone acetonide	Triamcinolone acetonide	Micro Labs	SUPPL-15	Approved labeling supplement

The FDA database designates Ameluz and Hyrnuo submissions as efficacy supplements. When detailed clinical trial data or revised prescribing information have not yet posted to the public Drugs@FDA label repository, clinicians must consult updated package inserts to verify specific modifications to dosing, safety warnings, or patient subgroups.

Medical devices

The FDA's monthly downloadable 510(k) file recorded four premarket notifications cleared between September 5 and September 11, 2026. All four clearances carry decision dates of September 5 or September 6. 3

Cleared 510(k) devices

510(k) number	Device trade name	Applicant	Decision date	Classification and regulation
K254135	LipoSurg ARTIST	NOUVAG AG	Sep. 5, 2026	Suction system for lipoplasty tissue removal (Product code: QPB)
K261684	FreezeSpray TA	Cryosurgery, Inc.	Sep. 5, 2026	Vapocoolant device for topical cooling (Product code: MLY)
K260396	KCS rTMS Therapy System (MetaStim 100, MetaStim 100A)	Fidelity BioPharma Co.	Sep. 6, 2026	Transcranial magnetic stimulator (21 CFR 882.5805; Product code: OBP)
K261131	Electrical Muscle Stimulator (AST-2012 models)	Shenzhen Osto Medical Technology Co., Ltd.	Sep. 6, 2026	Over-the-counter transcutaneous nerve and muscle stimulator (21 CFR 882.5890; Product codes: NUH, NGX)

The official CDRH decision records for these four submissions provide clearance dates, applicant names, and regulatory classifications, but the FDA database has not yet attached public 510(k) summary documents or statements of intended use. Clinicians and device purchasers should treat specific technological comparisons as pending until the agency publishes the complete engineering and clinical summaries. 8 9 10 11

Ledger coverage and PMA status

The CDRH premarket approval RSS feed recorded no PMA approvals, panel-track supplements, or 30-day notices dated September 5 through September 11, 2026. The most recent PMA decisions displayed in the feed carry decision dates through September 4, 2026. 4

Public reporting lags occur regularly in device data processing. The absence of entries between September 7 and September 11 reflects the captured status of public FDA files. Subsequent monthly file updates frequently incorporate additional clearance records retroactively.

What matters next

Scholar Rock launch metrics: Track commercial formulary determinations and early infusion adoption for Isembyld. Clinical teams must establish logistics for monthly intravenous infusions, while investors will assess uptake among patients already established on oral or intrathecal SMN2 therapies.
Oncology and neurology generic rollouts: Monitor commercial distribution announcements from Hetero Labs (ibrutinib) and Zhejiang Jutai (brivaracetam) to assess pricing discounts against reference brands.
Supplemental label updates: Review prescribing revisions for Ameluz and Hyrnuo once the FDA releases updated label PDFs detailing the underlying efficacy supplement data.
CDRH data updates: Recheck the CDRH database in subsequent cycles for 510(k) summary postings for K254135, K261684, K260396, and K261131, alongside mid-September clearance additions.